Cell Line Models
We Understand Cell Lines! Leverage our expert, comprehensive CRISPR/Cas9 cell line modeling service for a stress-free research. With 1300+ unique cell line models engineered from >200 distinct mammalian cell lines, we can engineer perfectly suited cell line models for your research’s specifications using highly optimized and efficient CRISPR/Cas9 genome editing strategies and protocols:
- Engineer a variety of mutations; or correct mutations
- Variety of cell lines: cancer, hard-to-transfect, blood lineage, stem cell lines and many more
- Start-to finish cell line generation workflow; optional downstream cell line validation
- Custom deliverables: homozygous/ heterozygous clones; point mutation with/without silent mutation
- >97% success rate; turnaround time as fast as 2 months
Cell Line Model Generation Categories
CRISPR/Cas9
CRISPR/Cas9 Genome
Editing in
Stem Cells
.jpg)
CRISPR/Cas9 Cell Line
Service - Hematopoietic Cells
(Jurkat and TF-1)
Products and Services
| Catalog ID# | Product Name | Price | ||
|---|---|---|---|---|
Supporting Material
Brochure/Flyer:
Posters:
Webinar:
Technical Details
More than 1300 unique cell line models engineered from >200 distinct parental cell lines!
Selected list of successfully modified mammalian cell lines# by ASC:
Cell |
Species |
Tissue |
Cell Type |
Disease |
Blood Lineage Cells: |
||||
| BCWM-1* | Human | Bone marrow | Lymphoplasmacytic | Waldenstrom macroglobulinemia |
| EML | Mouse | Bone marrow | Basophil | Normal |
| FTC-133 | Human | Thryoid | Thyrocytes | Follicular thyroid carcinoma |
| HMC1.2 | Human | Peripheral blood | Mast cell | Mast cell leukemia |
| HUDEP-2 | Human | Umbilical cord | Erythroid progenitor | Normal |
| Jurkat | Human | Peripheral blood | T lymphocyte | Acute T cell leukemia |
| Jurkat (Clone E6-1) | Human | Peripheral blood | T lymphocyte | Acute T cell leukemia |
| JVM2 | Human | Peripheral blood | Lymphoblast | Mantle Cell Lymphoma |
| K562 | Human | Bone Marrow | Lymphoblast | Chronic myelogenous leukemia (CML) |
| KG-1 | Human | Bone | Lymphoblast | Acute myelogenou leukemia |
| KHYG-1* | Human | Peripheral blood | T lymphocyte | Natural killer cell leukemia |
| MOLM-13 | Human | Peripheral blood | Monocyte-like | Acute myeloid leukemia |
| MWCL-1 | Human | Bone marrow | Lymphoplasmacytic | Waldenstrom macroglobulinemia |
| RAW 264.7 | Mouse | Ascites | Macrophage | Abelson murine leukemia virus-induced tumor |
| Sp2/0-Ag14 | Mouse | Spleen | B lymphocyte | Normal |
| T2 | Human | Blood lineage | Lymphocyte | |
| TF-1 | human | Bone marrow | Erythroblast | Erythroleukemia |
| U937 | Human | Lymphocyte | Monocyte | Histiocytic lymphoma |
Cancer Cell Lines: |
||||
| 22RV1 | Human | Prostrate | Epithelial | Carcinoma |
| 786-0 | Human | Kidney | Epithelial | Renal cell adenocarcinoma |
| A375 | Human | Skin | Epithelial | Malignant melanoma |
| A549 | Human | Lung | Epithelial | Carcinoma |
| AGS | Human | Stomach | Epithelial | Gastric adenocarcinoma |
| B16-F10 | Mouse | Skin | Spindle/Epithelial-like | Melanoma |
| CL-40 | Human | Colon | Epithelial | Colon carcinoma |
| CT-26 | Mouse | Colon | Fibroblast | Carcinoma |
| DLD-1 | Human | Colon | Epithelial | Dukes' type C, colorectal adenocarcinoma |
| H2030 | Human | Lung | Epithelial | Non-small cell lung cancer |
| H716 | Human | Cecum | Epithelial | Colorectal carcinoma |
| HAC15 | Human | Adrenal | Epithelial-like | Carcinoma |
| HBE | Human | Lung | Epithelial | Lung cancer |
| HCT116 | Human | Colon | Epithelial | Colorectal carcinoma |
| HEK293 | Human | Embryonic kidney | Epithelial | |
| HEK293T | Human | Embryonic kidney | Epithelial | |
| Hela | Human | Cervix | Epithelial | Cervical cancer |
| HepG2 | Human | Liver | Epithelial | Hepatocellular carcinoma |
| HT1080 | Human | Coonective Tissue | Epithelial | Fibrosarcoma |
| HT29 | Human | Colon | Epithelial | Colorectal carcinoma |
| Huh7 | Human | Liver | Epithelial | Hepatocellular carcinoma |
| KYSE-270 | Human | Esophagus | Epitheloid | Esophageal squamous cell carcinoma |
| LNCaP | Human | Prostrate | Epithelial | Prostrate adenocarcinoma |
| MALME-3M | Human | Lung (metastatic) | Fibroblast | Malignant melanoma |
| Mc-38 | Mouse | Colon | Epithelial | Colon adenocarcinoma |
| MCF7 | Human | Mammary gland | Epithelial | Adenocarcinoma |
| mEERL | Mouse | Lung | Epithelial | Orpharyngeal squamous cell carcinoma |
| MKN1 | Human | Lymph node | Epithelial | Gastric adenosquamous carcinoma |
| Neuro-2a | Mouse | Brain | Neuroblast | Neuroblastoma |
| PANC1 | Human | Pancreas/duct | Epithelial | Epithelioid carcinoma |
| PC-3M | Human | Bone | Epithelial | Prostrate carcinoma |
| RCS | Rat | n/a | Chondrocytes | Chondrosarcoma |
| Renca | Mouse | Kidney | Epithelial | Renal adenocarcinoma |
| RKO | Human | Colon | Epithelial | Carcinoma |
| SBC-5 | Human | Lung | n/a | Small cell lung carcinoma |
| SCC-35 | Human | n/a | Squamous cells | Head and neck cancer |
| SH-SY5Y | Human | Bone Marrow | Epithelial | Neuroblastoma |
| SH-SY5Y (with eGFP) | Human | Bone Marrow | Epithelial | Neuroblastoma |
| T47D | Human | Mammary gland | Epithelial | Ductal carcinoma |
| T84 | Human | Colon | Epithelial | Colorectal carcinoma |
| TC32 | Human | Bone | n/a | Neuroectodermal carcinoma |
| TOV-112D | Human | Ovary | Epithelial | Primary adenocarcinoma |
| U-2 OS | Human | Bone | Epithelial | Osteosarcoma |
Other Cell Lines: |
||||
| 3617 | Mouse | Mammary gland | Epithelial | Normal |
| 3T3-Swiss albino | Mouse | Embryo | Fibroblast | Normal |
| 4T1* | Mouse | Mammary gland | Epithelial | Normal |
| AGMK GL37 | African Green Monkey | Kidney | Epithelial | Normal |
| ARPE-19 | Human | Eye | Retinal pigmented Epithelium | Normal |
| BEAS-2B | Human | Lung | Epithelial | Normal |
| BJ-hTERT | Human | Skin (foreskin) | Fibroblast | Normal |
| CHO-S | Hamster | Ovary | Epithelial-like | |
| cTEC C9() | Mouse | Thymus | Epithelial | cTEC |
| Fibroblast (primary) | Human | Primary fibroblast | Normal | |
| HaCaT | Human | Skin | Keratinocyte | Normal |
| HMEC | Human | Dermal endotheliym | Dermal microvascular endothelium | |
| hTERT RPE | Human | Retina (pigmented epithelium) | Epithelial | |
| IDH4 | Human | Lung | Fibroblast | IDH |
| MCF10 | Human | Mammary gland | Epithelial | Fibrocystic disease |
| NIH/3T3 | Mouse | Embryo | Fibroblast | Normal |
| PCCL3 | Rat | Thyroid | Epithelium | |
| Podocyte | Human | Kidney | Primary | |
| SW10 | Mouse | Neuronal Schwann cell | Neuronal | |
Stem Cells (iPSC/ ESC): |
||||
| Induced pluripotent stem cells (iPSC) | Human | PBMC/ Skin/ Cord blood | PBMC/Fibroblasts | Normal/ Disease |
| Embryonic stem cells (ESC) | Human | inner cell mass | Embryonic stem cell | Normal/ Disease |
| iPSC | Mouse, Primate, Others | Skin | Fibroblast | Normal |
| ESC | Mouse, Rat, Macaque | inner cell mass | Embryonic stem cell | Normal |
* Inquire for details; # cell lines purchased by clients on ASC on behalf of clients.
Don’t see a cell line you are looking for? Ask for details. We always validate the cell lines in our cell line engineering workflow.
List of genetic modifications we can generate in your cell lines:
|
Gene knockout (KO): frame shift; fragment excision, stop cassette insertion, double KO |
Gene editing/ correction |
|
Gene knock-in (KI): point mutation, reporter gene, small/ large fragment insertion; locus-specific/ safe harbor locus |
Gene fusion/ translocation |
|
Controlled gene expression models: gene overexpression; conditional/ inducible gene expression; promoter modifications |
Removal of viral sequences |
|
Master cell line generation |
Gene replacement; gene therapy |
Don’t see a particular model you are interested in? Contact us to learn about the full scope of our expertise and get a cell line model engineered precisely to your project requirements.
Applications:
- Disease modeling for immuno-oncology, pharmacogenomic studies
- Drug discovery and drug efficacy and toxicity screening; drug combination studies
- Antibody validation
- Deriving diagnostic reference standards and materials
- Recombinant protein production in CHO cells
- Generation of TARGATT™ master cell lines by inserting an attP "docking site" for site-specific gene knock-in
For large DNA/ transgene insertion in cell lines, please refer to the TARGATT™ cell line editing services. The TARGATT™ integrase technology is a site-specific gene knock-in technology and is complementary to CRISPR/Cas9 technology. Both these technologies together offer a broader scope for engineering physiologically predictive and advanced cell line models.
We also offer lentivirus-based stable cell line generation for difficult-to-handle cell lines: integration-free lentivirus for CRISPR-lentivirus gene knockout; broad tropism lentiviruses for efficient stable gene knock-in.
Comprehensive Technology Platforms for Genome Editing
|
Methods |
Technical Advantage |
|
TARGATT™ phiC31 integrase |
|
|
CRISPR / Cas9 |
|
Publications
Applied StemCell publications and citations:
- Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019). Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Experimental & Molecular Medicine, 51(1), 3.
- Colomar-Carando, N., Meseguer, A., Jutz, S., Herrera-Fernández, V., Olvera, A., Kiefer, K., ... & Vicente, R. (2018). Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery. The Journal of Immunology, ji1800689.
- Tanic, J. (2018). A Role for Adseverin in the Invasion and Migration of MCF7 Breast Adenocarcinoma Cells (Doctoral dissertation).
- Lizarraga, S. B., Maguire, A. M., Ma, L., van Dyck, L. I., Wu, Q., Nagda, D., ... & Cowen, M. H. (2018). Human neurons from Christianson syndrome iPSCs reveal allele-specific responses to rescue strategies. bioRxiv, 444232.
- Tanaka, H., Kondo, K., Chen, X., Homma, H., Tagawa, K., Kerever, A., ... & Fujita, K. (2018). The intellectual disability gene PQBP1 rescues Alzheimer’s disease pathology. Molecular Psychiatry, 1.
- Yin, Y., Garcia, M. R., Novak, A. J., Saunders, A. M., Ank, R. S., Nam, A. S., & Fisher, L. W. (2018). Surf4 (Erv29p) binds amino-terminal tripeptide motifs of soluble cargo proteins with different affinities, enabling prioritization of their exit from the endoplasmic reticulum. PLoS biology, 16(8), e2005140.
-
Selvan, N., George, S., Serajee, F. J., Shaw, M., Hobson, L., Kalscheuer, V. M., ... & Schwartz, C. E. (2018). O-GlcNAc transferase missense mutations linked to X-linked intellectual disability deregulate genes involved in cell fate determination and signaling. Journal of Biological Chemistry, jbc-RA118.
-
Smalley, E. (2018). FDA warns public of dangers of DIY gene therapy. https://doi.org/10.1038/nbt0218-119
-
Chai, S., Wan, X., Ramirez-Navarro, A., Tesar, P. J., Kaufman, E. S., Ficker, E., ... & Deschênes, I. (2018). Physiological genomics identifies genetic modifiers of long QT syndrome type 2 severity. The Journal of clinical investigation, 128(3).
-
Boi, S., Ferrell, M. E., Zhao, M., Hasenkrug, K. J., & Evans, L. H. (2018). Mouse APOBEC3 expression in NIH 3T3 cells mediates hypermutation of AKV murine leukemia virus. Virology, 518, 377-384. https://doi.org/10.1016/j.virol.2018.03.014.
-
Molinski, S. V., et al. (2017). Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue. EMBO Molecular Medicine, e201607137.
-
Petrovic, P. B. (2017). Myosin Phosphatase Rho-interacting Protein Regulates DDR1-mediated Collagen Tractional Remodeling (Doctoral dissertation, University of Toronto (Canada)).
-
Peng, L., Zhang, H., Hao, Y., Xu, F., Yang, J., Zhang, R., ... & Chen, C. (2016). Reprogramming macrophage orientation by microRNA 146b targeting transcription factor IRF5. EBioMedicine, 14, 83-96.
-
Hu, J. K., Crampton, J. C., Locci, M., & Crotty, S. (2016). CRISPR-mediated Slamf1Δ/Δ Slamf5Δ/Δ Slamf6Δ/Δ triple gene disruption reveals NKT cell defects but not T follicular helper cell defects. PloS one, 11(5), e0156074.
-
Smalley, E. (2016). CRISPR mouse model boom, rat model renaissance. Nature Biotechnology. 34, 893–894.
-
Baker, M. (2014). Gene editing at CRISPR speed. Nature biotechnology, 32(4), 309-313.
